Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TQB 2825

Next Previous
Drug Profile

TQB 2825

Alternative Names: TQB-2825

Latest Information Update: 26 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chia Tai Tianqing Pharmaceutical Group
  • Class Antineoplastics; Bispecific antibodies; Immunotherapies
  • Mechanism of Action Cytotoxic T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diffuse large B cell lymphoma
  • No development reported Haematological malignancies

Most Recent Events

  • 26 Sep 2025 Shanghai Chia Tai Tianqing Pharmaceutical Technology Development plans phase III trial in Follicular lymphoma (Late-stage disease, Second-line therapy, Recurrent) in China (IV) (NCT07187960)
  • 22 Sep 2025 No development reported - Phase-I for Haematological malignancies (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT05489276)
  • 07 Aug 2025 Chia Tai Tianqing Pharmaceutical Group plans a phase-I trial for Haematological malignancies (Second-line therapy or greater) in China (SC), (NCT07110194)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top